Neoplastic Heterogeneity and Clinical Chemotherapy
Cancer chemotherapy is a modality in transition. In its early days, chemotherapy was viewed with skepticism by many, and its pioneers were forced to emphasize its positives in an aggressively defensive manner. In the early 1970s, chemotherapy appeared poised to possibly become a dominant modality. This was caused by the concept of adjuvant chemotherapy which appeared validated by the early relapse-free survival gains reported in the treatment of primary breast cancer. A decade later it is obvious that adjuvant chemotherapy is not a dramatic breakthrough and that the modality itself has plateaued in its ability to cure and palliate malignant disease.
KeywordsAdjuvant Chemotherapy Primary Disease Limb Salvage Biologic Heterogeneity Clinical Chemotherapy
Unable to display preview. Download preview PDF.
- 1.Carter SK, Bakowski M, Hellmann K: Chemotherapy of Cancer, 2nd edition. John Wiley and Sons, NY, 1981Google Scholar
- 2.Carter SK, Livingston RG, Glatstein E: Principles of Cancer Treatment. McGraw-Hill, NY, 1982Google Scholar
- 3.De Vita VT, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, 2nd edition. J.B. Lippincott Co., Philadelphia, 1985Google Scholar
- 5.Skipper HE, Simpson-Herren L: Relationship between Tumor Stem Cell Heterogeneity and Resistance to Chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA: Important Advances in Oncology, 1985. J.B. Lippincott, Philadelphia, pp. 63–78 1985Google Scholar